Funding for this research was provided by:
Text and Data Mining valid from 2019-01-03
Received: 12 November 2018
Accepted: 4 December 2018
First Online: 3 January 2019
Duality of interest
: No funding or writing assistance has been provided for this article. The author or institutions with which he is associated has had funding for his research, advisory and/or lecturing activities from the manufacturers of every one of the medications listed in Tables InternalRef removed, InternalRef removed and InternalRef removed, and in particular in regard of sitagliptin, albiglutide and canagliflozin, and from many competing products. This then specifically includes AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hanmi, Janssen, Merck (MSD), Novo Nordisk, Sanofi, and Takeda.